Taiho Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taiho Pharmaceutical Co., Ltd., explained in plain language.
-
New drug TAS-205 tested in phase 3 trial for duchenne muscular dystrophy
Disease control OngoingThis study tests a drug called TAS-205 in 104 people with Duchenne muscular dystrophy, a muscle-weakening disease. The goal is to see if TAS-205 helps with movement tasks like standing up from the floor and walking, and to check for side effects. Participants are either able to w…
Phase: PHASE3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New combo tackles resistant gut tumors in early trial
Disease control OngoingThis early-phase study tests a new drug (TAS-116) combined with imatinib in people with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib alone. About 78 participants will receive different treatments to find the safest dose and see if the combo c…
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC